Boundless Bio, Common Stock Performance
| BOLD Stock | USD 10.00 0.10 1.01% |
The firm shows a Beta (market volatility) of 0.25, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Boundless Bio,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Boundless Bio, is expected to be smaller as well. Boundless Bio, Common has an expected return of -1.34%. Please make sure to confirm Boundless Bio, Common accumulation distribution, and the relationship between the potential upside and day median price , to decide if Boundless Bio, Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Boundless Bio, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 1.01 | Five Day Return (17.90) | Year To Date Return 100 M | Ten Year Return (33.91) | All Time Return (33.91) |
1 | Boundless Bio Prices 6.25M Share IPO at 16sh | 03/28/2024 |
2 | USTA SETS BOLD NEW GOAL TO MAKE U.S. THE WORLDS 1 TENNIS-PLAYING NATION BY 2035 | 04/03/2024 |
3 | Ra capital funds buy Boundless Bio shares worth 5 million | 04/04/2024 |
4 | Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA -Directed Therapy, BBI-355, at the American Association fo... | 04/08/2024 |
5 | Boundless Bio Announces First Patient Dosed in First-in-Human Phase 12 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications | 04/11/2024 |
6 | Disposition of 8681 shares by Thomas Soloway of Boundless Bio at 59.37 subject to Rule 16b-3 | 04/17/2024 |
7 | GEENA DAVIS INSTITUTE CELEBRATES 20TH ANNIVERSARY WITH A BOLD REBRAND | 04/25/2024 |
| Begin Period Cash Flow | 11.5 M |
Boundless |
Boundless Bio, Relative Risk vs. Return Landscape
If you would invest 1,425 in Boundless Bio, Common on February 2, 2024 and sell it today you would lose (425.00) from holding Boundless Bio, Common or give up 29.82% of portfolio value over 90 days. Boundless Bio, Common is currently does not generate positive expected returns and assumes 5.0648% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Boundless, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Boundless Bio, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Boundless Bio,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Boundless Bio, Common, and traders can use it to determine the average amount a Boundless Bio,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2644
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BOLD |
Estimated Market Risk
| 5.06 actual daily | 44 56% of assets are more volatile |
Expected Return
| -1.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.26 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Boundless Bio, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Boundless Bio, by adding Boundless Bio, to a well-diversified portfolio.
Boundless Bio, Fundamentals Growth
Boundless Stock prices reflect investors' perceptions of the future prospects and financial health of Boundless Bio,, and Boundless Bio, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Boundless Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 145.93 M | ||||
| Shares Outstanding | 22.24 M | ||||
| Price To Earning | (7.22) X | ||||
| EBITDA | (53.84 M) | ||||
| Net Income | (49.43 M) | ||||
| Cash And Equivalents | 351.46 M | ||||
| Cash Per Share | 7.68 X | ||||
| Total Debt | 2.19 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.80 X | ||||
| Book Value Per Share | 8.38 X | ||||
| Cash Flow From Operations | (46.85 M) | ||||
| Market Capitalization | 301.12 M | ||||
| Total Asset | 129.89 M | ||||
| Retained Earnings | (136.11 M) | ||||
| Working Capital | 114.84 M | ||||
| Current Asset | 99.64 M | ||||
| Current Liabilities | 104 K | ||||
About Boundless Bio, Performance
To evaluate Boundless Bio, Common Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Boundless Bio, generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Boundless Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Boundless Bio, Common market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Boundless's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | 0.39 | 0.41 |
Things to note about Boundless Bio, Common performance evaluation
Checking the ongoing alerts about Boundless Bio, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Boundless Bio, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Boundless Bio, generated a negative expected return over the last 90 days | |
| Boundless Bio, has high historical volatility and very poor performance | |
| Net Loss for the year was (49.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Boundless Bio, Common currently holds about 351.46 M in cash with (46.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68. | |
| Latest headline from prnewswire.com: GEENA DAVIS INSTITUTE CELEBRATES 20TH ANNIVERSARY WITH A BOLD REBRAND |
- Analyzing Boundless Bio,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Boundless Bio,'s stock is overvalued or undervalued compared to its peers.
- Examining Boundless Bio,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Boundless Bio,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Boundless Bio,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Boundless Bio,'s stock. These opinions can provide insight into Boundless Bio,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Boundless Stock analysis
When running Boundless Bio,'s price analysis, check to measure Boundless Bio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio, is operating at the current time. Most of Boundless Bio,'s value examination focuses on studying past and present price action to predict the probability of Boundless Bio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio,'s price. Additionally, you may evaluate how the addition of Boundless Bio, to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Boundless Bio,'s industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.33) | Return On Equity (0.53) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.